A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 48
- Population
- ALL · 50 Years to 80 Years
- Duration
- 2026-02-12 to 2027-06-30
- Intervention
- GB10
- Comparator
- Not reported
- Outcomes measured
- The incidence and severity of ocular adverse events — From enrollment to the end of treatment at 12 weeks; The incidence and severity of non-ocular adverse events — From enrollment to the end of treatment at 12 weeks; (SAD) The change in best corrected visual acuity (BCVA) from baseline after 4 weeks of treatment — From enrollment to t…; (MAD) The change in best corrected visual acuity (BCVA) from baseline after 12 weeks of treatment — From enrollment to…; (SAD) Change in central retinal subfield thickness (CST) from baseline at 4 weeks of treatment — From enrollment to the…; (MAD) Change in central retinal subfield thickness (CST) from baseline at 12 weeks of treatment — From enrollment to th…; Time of receiving rescue therapy for nAMD activity — From enrollment to the end of treatment at 12 weeks; Positive rate of anti-drug antibody and neutralizing antibody of GB10 — From enrollment to the end of treatment at 12 w…; Area under the drug-time curve from 0 to time t of GB10 — From enrollment to the end of treatment at 12 weeks; Area under the curve at the time of 0-infinity of GB10 — From enrollment to the end of treatment at 12 weeks; Peak concentration of GB10 — From enrollment to the end of treatment at 12 weeks; Peak time of GB10 — From enrollment to the end of treatment at 12 weeks; Clearance rate of GB10 — From enrollment to the end of treatment at 12 weeks; Half-life of GB10 — From enrollment to the end of treatment at 12 weeks; VEGF concentration — From enrollment to the end of treatment at 12 weeks; Ang2 concentration — From enrollment to the end of treatment at 12 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.